Lexaria signs PegBio MTA; potential cross-border tech access catalyst
Lexaria Bioscience disclosed a Material Transfer Agreement with PegBio Ltd., a Hong Kong-listed partner. The deal suggests PegBio may gain access to Lexaria’s technology for development purposes, potentially unlocking future milestones or royalties. The stock reacted positively with a Thursday surge, though the absence of disclosed terms leaves the magnitude of upside uncertain.
View signal analysis